title: [Interruption of biological drugs in patients affected with inflammatory diseases].
abstract: The use of biological drugs in the treatment of inflammatory rheumatic diseases, bowel diseases, and psoriasis has increased. Patients receiving a biological drug are invariably under the supervision of a specialized physician, but many are also attending basic healthcare clinics. Every physician taking care of a patient receiving a biological drug should be aware of the principles of interruption. In the present article we will focus on common situations, where an interruption of a biological drug must be considered in the treatment of these inflammatory diseases.
authors.forename: Veli-Jukka
authors.initials: VJ
authors.lastname: Anttila
authors.forename: Johanna
authors.initials: J
authors.lastname: Haapamäki
authors.forename: Ritva
authors.initials: R
authors.lastname: Peltomaa
authors.forename: Tarja
authors.initials: T
authors.lastname: Tiippana-Kinnunen
authors.forename: Riitta
authors.initials: R
authors.lastname: Luosujärvi
mesh_terms: D001688:Biological Products / Q000008:administration & dosage*; D001691:Biological Therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011565:Psoriasis / Q000188:drug therapy*; D012216:Rheumatic Diseases / Q000188:drug therapy*
chemical_list: D001688:Biological Products